140 related articles for article (PubMed ID: 34790076)
1. Antithrombin III Supplementation in a Premature Infant: Is There a Target Antithrombin Level?
Shukla A; Braunreiter C
J Pediatr Pharmacol Ther; 2021; 26(8):850-856. PubMed ID: 34790076
[TBL] [Abstract][Full Text] [Related]
2. Effect of Exogenous Antithrombin Administration on Anti-Xa Levels in Infants Treated With Enoxaparin.
Logston BB; Rodman EA; Dinh KL; Placencia JL; Moffett BS; Rios DR
J Pediatr Pharmacol Ther; 2018; 23(4):315-319. PubMed ID: 30181723
[TBL] [Abstract][Full Text] [Related]
3. Higher doses of low-molecular-weight heparin (enoxaparin) are needed to achieve target anti-Xa concentrations in critically ill children*.
Schloemer NJ; Abu-Sultaneh S; Hanson SJ; Yan K; Hoffmann RG; Punzalan RC; Havens PL
Pediatr Crit Care Med; 2014 Sep; 15(7):e294-9. PubMed ID: 24901803
[TBL] [Abstract][Full Text] [Related]
4. Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis.
Corder A; Held K; Oschman A
Pediatr Blood Cancer; 2014 Jun; 61(6):1063-7. PubMed ID: 24375987
[TBL] [Abstract][Full Text] [Related]
5. Antithrombin III supplementation on extracorporeal membrane oxygenation: impact on heparin dose and circuit life.
Byrnes JW; Swearingen CJ; Prodhan P; Fiser R; Dyamenahalli U
ASAIO J; 2014; 60(1):57-62. PubMed ID: 24296776
[TBL] [Abstract][Full Text] [Related]
6. A Weight- and Anti-Xa-Guided Enoxaparin Dosing Protocol for venous thromboembolism Prophylaxis in intensive care unit Trauma Patients.
Bigos R; Solomon E; Dorfman JD; Ha M
J Surg Res; 2021 Sep; 265():122-130. PubMed ID: 33930618
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Antithrombin III Use in Achieving Anticoagulant Goals in Pediatric Patients.
Jones AJ; O'Mara KL; Kelly BJ; Samraj RS
J Pediatr Pharmacol Ther; 2017; 22(5):320-325. PubMed ID: 29042831
[TBL] [Abstract][Full Text] [Related]
8. The Use of Recombinant Antithrombin III in Pediatric and Neonatal ECMO Patients.
Todd Tzanetos DR; Myers J; Wells T; Stewart D; Fanning JJ; Sullivan JE
ASAIO J; 2017; 63(1):93-98. PubMed ID: 27861430
[TBL] [Abstract][Full Text] [Related]
9. Impact of antithrombin III and enoxaparin dosage adjustment on prophylactic anti-Xa concentrations in trauma patients at high risk for venous thromboembolism: a randomized pilot trial.
Droege ME; Droege CA; Philpott CD; Webb ML; Ernst NE; Athota K; Wakefield D; Dowd JR; Gomaa D; Robinson BHR; Hanseman D; Elterman J; Mueller EW
J Thromb Thrombolysis; 2021 Nov; 52(4):1117-1128. PubMed ID: 33978907
[TBL] [Abstract][Full Text] [Related]
10. IV Versus Subcutaneous Enoxaparin in Critically Ill Infants and Children: Comparison of Dosing, Anticoagulation Quality, Efficacy, and Safety Outcomes.
Diab YA; Ramakrishnan K; Ferrell B; Chounoune R; Alfares FA; Endicott KM; Rooney S; Corcoran J; Zurakowski D; Berger JT; Shankar V; Nath DS
Pediatr Crit Care Med; 2017 May; 18(5):e207-e214. PubMed ID: 28296662
[TBL] [Abstract][Full Text] [Related]
11. Treatment and follow-up of venous thrombosis in the neonatal intensive care unit: a retrospective study.
Bohnhoff JC; DiSilvio SA; Aneja RK; Shenk JR; Domnina YA; Brozanski BS; Good M
J Perinatol; 2017 Mar; 37(3):306-310. PubMed ID: 27906197
[TBL] [Abstract][Full Text] [Related]
12. Thromboelastogram-guided enoxaparin dosing does not confer protection from deep venous thrombosis: a randomized controlled pilot trial.
Louis SG; Van PY; Riha GM; Barton JS; Kunio NR; Underwood SJ; Differding JA; Rick E; Ginzburg E; Schreiber MA
J Trauma Acute Care Surg; 2014 Apr; 76(4):937-42; discussion 942-3. PubMed ID: 24662855
[TBL] [Abstract][Full Text] [Related]
13. Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients.
Streif W; Goebel G; Chan AK; Massicotte MP
Arch Dis Child Fetal Neonatal Ed; 2003 Sep; 88(5):F365-70. PubMed ID: 12937038
[TBL] [Abstract][Full Text] [Related]
14. Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant.
Michaels LA; Gurian M; Hegyi T; Drachtman RA
Pediatrics; 2004 Sep; 114(3):703-7. PubMed ID: 15342842
[TBL] [Abstract][Full Text] [Related]
15. Optimal dose of enoxaparin in critically ill trauma and surgical patients.
Rutherford EJ; Schooler WG; Sredzienski E; Abrams JE; Skeete DA
J Trauma; 2005 Jun; 58(6):1167-70. PubMed ID: 15995464
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?
Priglinger U; Delle Karth G; Geppert A; Joukhadar C; Graf S; Berger R; Hülsmann M; Spitzauer S; Pabinger I; Heinz G
Crit Care Med; 2003 May; 31(5):1405-9. PubMed ID: 12771610
[TBL] [Abstract][Full Text] [Related]
17. Capped antithrombin III dosing is cost effective in the management of asparaginase-associated thrombosis.
Young J; Sawyer J; Jenkins M; O'Brien M; Luchtman-Jones L; Breese EH
Pediatr Blood Cancer; 2019 Jun; 66(6):e27719. PubMed ID: 30900794
[TBL] [Abstract][Full Text] [Related]
18. THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents.
Greiner J; Schrappe M; Claviez A; Zimmermann M; Niemeyer C; Kolb R; Eberl W; Berthold F; Bergsträsser E; Gnekow A; Lassay E; Vorwerk P; Lauten M; Sauerbrey A; Rischewski J; Beilken A; Henze G; Korte W; Möricke A;
Haematologica; 2019 Apr; 104(4):756-765. PubMed ID: 30262570
[TBL] [Abstract][Full Text] [Related]
19. Adequate Antithrombin III Level Predicts Survival in Severe COVID-19 Pneumonia.
Joshi D; Manohar S; Goel G; Saigal S; Pakhare AP; Goyal A
Cureus; 2021 Oct; 13(10):e18538. PubMed ID: 34754684
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients.
Haas CE; Nelsen JL; Raghavendran K; Mihalko W; Beres J; Ma Q; Forrest A
J Trauma; 2005 Dec; 59(6):1336-43; discussion 1343-4. PubMed ID: 16394906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
